<DOC>
	<DOCNO>NCT00453310</DOCNO>
	<brief_summary>RATIONALE : Sunitinib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . PURPOSE : This phase II trial study well sunitinib work treat patient metastatic germ cell tumor relapse responded treatment .</brief_summary>
	<brief_title>Sunitinib Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed Not Responded Treatment</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy sunitinib malate patient refractory relapse metastatic germ cell tumor . Secondary - Determine safety drug patient . - Determine time tumor response duration tumor response patient treated drug . OUTLINE : This open-label study . Patients receive oral sunitinib malate daily day 1-28 . Treatment repeat every 6 week 9 course absence disease progression unacceptable toxicity . After completion study therapy , patient follow 28 day periodically thereafter .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Teratoma</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm seminoma nonseminoma germ cell tumor ( GCT ) Refractory relapse disease Metastatic disease Progressive disease prior cisplatinbased chemotherapy AND meet 1 follow criterion salvage therapy : Not candidate potentially curative therapy Received prior highdose chemotherapy regimens Declines potentially curative therapy ( mediastinal GCT primary refractory GCT ) Measurable disease* , define 1 following : At least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan Elevation alphafetoprotein &gt; 15 ng/mL and/or elevation human chorionic gonadotropin &gt; 2.2 mIU/L NOTE : *Patients radiographically measurable disease must ≥ 1 site undergone prior irradiation PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9.0 g/dL Creatinine ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN AST ALT ≤ 2.5 time ULN ( unless elevate liver function abnormality due underlying malignancy ) LVEF ≥ 50 % MUGA No grade 3 hemorrhage within past 4 week None follow within past 6 month : Myocardial infarction Severe unstable angina Coronary peripheral artery bypass graft Symptomatic congestive heart failure Cerebrovascular accident transient ischemic attack Pulmonary embolism No prolong QTc interval ( i.e. , QTc &gt; 450 msec male &gt; 470 msec female ) No ongoing cardiac dysrhythmias ≥ grade 2 No uncontrolled hypertension , define blood pressure &gt; 150/100 mm Hg despite optimal therapy No active infection No severe acute chronic medical psychiatric condition laboratory abnormality would preclude study compliance , accord study investigator Not pregnant nursing Negative sonogram require exclude pregnancy Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior sunitinib malate More 4 week since prior major surgery recover More 4 week since prior radiotherapy recover Concurrent palliative radiotherapy metastatic lesion ( ) allow provide ≥ 1 measurable lesion irradiate No concurrent therapeutic dos warfarin Lowdose oral warfarin ( 2 mg daily ) prophylaxis treatment heparin product prophylactic treatment dos allow No concurrent investigational approve anticancer therapy , include chemotherapy , biologic response modifier , hormone therapy , immunologicbased treatment Concurrent participation supportive care nontreatment trial ( e.g. , qualityoflife laboratory analysis ) allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>ovarian choriocarcinoma</keyword>
	<keyword>ovarian immature teratoma</keyword>
	<keyword>ovarian mature teratoma</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>testicular choriocarcinoma</keyword>
	<keyword>testicular seminoma</keyword>
	<keyword>testicular yolk sac tumor</keyword>
	<keyword>ovarian dysgerminoma</keyword>
	<keyword>ovarian embryonal carcinoma</keyword>
	<keyword>ovarian yolk sac tumor</keyword>
	<keyword>ovarian monodermal highly specialized teratoma</keyword>
	<keyword>ovarian polyembryoma</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>ovarian mixed germ cell tumor</keyword>
	<keyword>testicular choriocarcinoma embryonal carcinoma</keyword>
	<keyword>testicular choriocarcinoma seminoma</keyword>
	<keyword>testicular choriocarcinoma teratoma</keyword>
	<keyword>testicular choriocarcinoma yolk sac tumor</keyword>
	<keyword>testicular embryonal carcinoma seminoma</keyword>
	<keyword>testicular embryonal carcinoma teratoma seminoma</keyword>
	<keyword>testicular embryonal carcinoma teratoma</keyword>
	<keyword>testicular embryonal carcinoma yolk sac tumor seminoma</keyword>
	<keyword>testicular embryonal carcinoma yolk sac tumor</keyword>
	<keyword>testicular yolk sac tumor teratoma seminoma</keyword>
	<keyword>testicular yolk sac tumor teratoma</keyword>
	<keyword>testicular embryonal carcinoma</keyword>
	<keyword>recurrent extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>recurrent extragonadal seminoma</keyword>
	<keyword>stage IV extragonadal non-seminomatous germ cell tumor</keyword>
	<keyword>stage IV extragonadal seminoma</keyword>
	<keyword>recurrent extragonadal germ cell tumor</keyword>
	<keyword>testicular immature teratoma</keyword>
	<keyword>testicular mature teratoma</keyword>
	<keyword>adult teratoma</keyword>
</DOC>